The comparators presented in Table 5 have been deemed appropriate by clinical experts. Comparators may be recommended (appropriate) practice, rather than actual practice. Comparators are not restricted to drugs but may be devices or procedures. Costs are the sponsor’s list prices, unless otherwise specified. Existing Product Listing Agreements are not reflected in the table; as a result, the table may not represent the actual costs to public drug plans.
Publication Details
Copyright
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Pharmacoeconomic Review Report: Icosapent Ethyl (Vascepa): (HLS Therapeutics Inc.): Indication: Prevention of cardiovascular events in statin-treated patients [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Aug. Appendix 1, Cost Comparison.